Sponsored by:
Facebook (FB)
JP Morgan (JPM)
AutoZone (AZO)
Yahoo (YHOO)
Focus Stocks
Featured Stories
Medtronic Reports Fourth Quarter Earnings
Cracker Barrel Reports Earnings, Increases Guidance
Best ETFs For Facebook Exposure
Is Yum! Brands Closing in to Support?
Intuitive Surgical Bullish Signs
Forest Laboratories Ready for its Quarterly Earnings Release
Published on Friday, 13 January 2012 10:12 Written by Gerard Lerod
New York, January 13th (TradersHuddle.com) - Shares of Forest Laboratories, Inc. (NYSE:FRX) are trading lower by -0.93% ahead of its
quarterly earnings release. Forest Laboratories, the maker of branded and generic forms of ethical drug products is expected to release its quarterly results on January 17th.
Wall Street Analysts consensus calls for a profit of $1.01 a share on $1.18 billion revenue.
Forest Laboratories estimates have a range of $0.34 a share. The high estimate calls for profit of $1.23 a share and the low estimate is calling for a profit of $0.89 a share, a year ago for the quarter the company reported $1.34 a share.
Forest Laboratories, Inc. (NYSE:FRX) develops, manufactures, and sells branded and generic forms of ethical drug products. The Company also manufactures non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses.
Related Articles
- Forest and Almirall to Present Aclidinium Bromide Clinical Data at the American Thoracic Society (ATS) International Conference
- Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association (APA) Annual Meeting
- New Ratings ( FRX, NEPT, PDCO )
- Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder
- Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012
- Forest Laboratories, Inc. to Host Investor Meeting to Review Company’s Late-Stage Product Development Pipeline and Commercialization Strategy
- Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings Per Share of $0.72 Including $0.06 Per Share of Acquisition Amortization
- Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2012 Fourth Quarter Earnings
- Forest Laboratories, Inc. Announces Buyout of Bystolic Royalties from Janssen Pharmaceutica NV
- Forest Laboratories and Almirall Announce FDA has Extended the Review Period for Aclidinium Bromide
Related Partner Headlines
- Think Like the Father of Value Investing - TheStreet.com
- Notable Call Options Activity in Forest Laboratories - Benzinga
- Forest Laboratories and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients with Major Depressive Disorder - Benzinga
- From Earlier: Forest Laboratories, Inc. and Gedeon Richter Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia - Benzinga
- From Earlier: Forest Laboratories Receives European Marketing Approval for Colobreathe Dry Powder Inhaler - Benzinga
- From Earlier: Forest and Almirall Announce Positive FDA Advisory Committee's Recommendation for Approval of Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease - Benzinga
- Analysts' Actions: GOOG, FRX, JBHT, KSU - TheStreet.com
- Forest Labs Posts Weak Quarter - TheStreet.com
What’s the next under-$10 stock that could be ready to skyrocket? Find out now when you join David Peltier at Stocks Under $10.
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
